Longeveron sets mid-September for ELPIS II HLHS trial data release, extending cash runway into late 2026.
Longeveron announced plans to release ELPIS II trial data for Hypoplastic Left Heart Syndrome in mid-September, a key milestone for its stem cell therapy pipeline. The company also extended its cash runway into Q4 2026, easing near-term liquidity concerns.
Management highlighted progress across four development programs, including Alzheimer’s disease and pediatric dilated cardiomyopathy. The Q2 2026 update reiterated laromestrocel’s potential but offered no new financial guidance.
Shares of LGVN rose modestly following the announcement, reflecting investor optimism about the upcoming data readout and extended funding horizon.